3Ruddy S Harris Jr ED, Sledge CB. Kelley's textbook of rheumatology [M]. 6th ed. Philadelphia: W. B. Saunders Company, 2001: 1039 - 1054.
4van der Linden S, Valkenhurg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylilis. A proposal for modification of the New York eriteria[J . Arthritis Rheum. 1984, 27(4): 361 -368.
5Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index[J]. J Rheumatol, 1994, 21 (12): 2286 -2291.
6Calin A, Garrett S, Whitelock fl, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index [J]. J Rheumatol, 1994, 21(12): 2281 -2285.
7Dalyan M, Guner A, Tuncer S, et al. Disability in ankylosing spondylitis[J].Disabil Rehabil, 1999, 21 (2): 74 -79.
8Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha [J]. N Engl J Med, 2002, 346(18) : 1349 - 1356.
9Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanereept treatment in patients with active ankylosing spondylitis [ J ]. Arthritis Rheum, 2003, 48(6) : 1667 - 1675.
10[9]Marco Barbieri,John B.Wong,Michael Drummond.The Cost Effectiveness of Infliximab for Severe Treatment-Resistant Rheumatoid Arthritis in the UK.Pharmacoeconomics,2005,23(6):607-618
